Dose escalation schedule: difference between revisions
Diff·revision 3 → 4·03:52, 4 Nov 2024
Difference between revision 3 and revision 4 of Dose escalation schedule. 2 lines changed; the page grew by 301 bytes.
| Revision 3 — 12:01, 22 Oct 2024 BUD_Bertram (talk) add the diluent volume the example assumes 1,918 bytes ±0 | Revision 4 — 03:52, 4 Nov 2024 EscalationEira (talk) split overlong sentence 2,219 bytes +301 | ||
|---|---|---|---|
| 15 | The insulinotropic and appetite effects do not attenuate in the same way, so the adaptation is selective: tolerability improves while efficacy is retained. This asymmetry is what makes the strategy work at all. | 15 | The insulinotropic and appetite effects do not attenuate in the same way, so the adaptation is selective: tolerability improves while efficacy is retained. This asymmetry is what makes the strategy work at all. |
| 16 | 16 | ||
| + | 17 | The four-week step interval matches the pharmacokinetics. With a half-life of about seven days, steady state is reached in four to five weeks, so a step held for four weeks is assessed at close to its full expression. A shorter step assesses a dose whose effect is still increasing.{{r|knudsen2019}} | |
| + | 18 | ||
| 17 | == References == | 19 | == References == |
| 18 | {{reflist}} | 20 | {{reflist}} |